HELICOBACTER PYLORI INFECTION AND CHRONIC iron deficiency anemia: FEATURES of COMBINED COURSE AND THERAPY


I.V. Maev, S.A. Kochetov, A.A. Samsonov, D.N. Andreev, Yu.A. Lezhneva

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow
Purpose: evaluation of pathogenesis and clinical manifestations of H. pylori infection in patients with iron deficiency anemia (IDA) and the assessment of their possible association with variants of the disease, duration of history, gender and age of patients.
Material and Methods: The study included 120 patients infected with H. pylori, which subsequently have been divided into two groups. The main group consisted of 70 H. pylori-infected and suffering from iron deficiency anemia patients. Patients of the main groups were randomly divided into two homogeneous groups according to the therapy: 1a subgroup received eradication therapy (ET): amoxicillin (1000 mg twice a day), clarithromycin (500 mg twice a day), esomeprazole 20 mg twice a day for 10 days, then transition to ferrous iron preparations in combination with ascorbic acid after the ET course; 1b subgroup received only a divalent iron preparations in combination with ascorbic acid. The control group (50 persons) consisted of patients infected with H. pylori receiving ET. Infection with H. pylori and control of eradication were confirmed by urea breath test using the Helic test system. Evaluation of the effectiveness of the IDA correction was performed by the monitoring of hemoglobin (Hb) levels, blood color index, total iron binding capacity, ferritin and serum iron. Follow-up assessments of patients were performed on 14th, 28th and 56th day of treatment.
Results: Analysis of anemic and sideropenic syndromes on 14th and 28th day of treatment of two subgroups of patients has shown that early response to therapy has been achieved in subgroup 1a. On the 28th day of treatment, the mean Hb level among patient of subgroups 1a was 117.8 g/l (± 29.3 g/l), in patients of subgroup 1b - 104.2 g / l (± 15.6 g/l) (P <0.05). On the 56 th day of treatment, all patients achieved the target values ​​corresponding to the normal Hb level. Dynamics of blood color index on the 28th and 56th day of the study was also significant in all groups; blood color indices in subgroup 1a were 0.09 and 0.15, respectively, in the subgroup 1b - 0.06 and 0.014, respectively. Moreover, among patients of subgroup 1a target levels were achieved in most patients on the 28th day of treatment (P <0.05). The effectiveness of ET was 80.0% (28 patients) in the subgroup 1a and 82.0% (41 patients) in the control group.
Conclusion: ET in patients suffering from chronic iron deficiency anemia allows to achieve a more rapid response to therapy with oral iron preparations, which is confirmed by laboratory parameters.

Literature


  1. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М., 2015.
  2. Tonkic A., Tonkic M., Lehours P., Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2012;17(Suppl 1):1–8.
  3. Маев И.В., Самсонов А.А., Андреев Д.Н. Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;8:4–12.
  4. Hagymasi K., Tulassay Z. Helicobacter pylori infection: new pathogenetic and clinical aspects. World J. Gastroenterol. 2014;20(21):6386–99.
  5. Malfertheiner P., Megraud F., O'Morain C., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J. Management of Helicobacter Pylori infection – Maastricht IV. Florence Consensus Report Gut. 2012;61:646–64.
  6. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций.Тер. архив. 2014;3:94–9.
  7. Маев И.В., Дичева Д.Т., Андреев Д.Н., Субботина Ю.С. Трудности диагностики железодефицитной анемии. РЖГГК. 2014;3:98–103.
  8. WHO/NHD. Iron Deficiency Anaemia. Assessment, Prevention and Control: A guide for programme managers, 2001.
  9. Ciacci C., Sabbatini F., Cavallaro R., Castiglione F., Di Bella S., Iovino P., Palumbo A., Tortora R., Amoruso D., Mazzacca G. Helicobacter pylori impairs iron absorption in infected individuals. Dig Liver Dis. 2004;36(7):455–60.
  10. Baysoy G., Ertem D., Ademoglu E., Kotiloglu E., Keskin S., Pehlivanoglu E. Gastric histopathology, iron status and iron deficiency anemia in children with Helicobacter pylori infection. J. Pediatr. Gastroenterol. Nutr. 2004;38(2):146–51.
  11. Dhaenens L., Szczebara F., Van Nieuwenhuyse S., Husson M.O. Comparison of iron uptake in different Helicobacter species. Res Microbiol. 1999;150(7):475–81.
  12. Annibale B., Capurso G., Delle Fave G. The stomach and iron deficiency anaemia: a forgotten link. Dig Liver Dis. 2003;35(4):288–95.
  13. Perez-Perez G.I., Israel D.A. Role of iron in Helicobacter pylori: its influence in outer membrane protein expression and inpathogenicity. Eur. J. Gastroenterol. Hepatol. 2000;12:1263–65.
  14. Baysoy G., Ertem D., Ademoglu E., Kotiloglu E., Keskin S., Pehlivanoglu E. Gastric Histo-pathology, Iron Status and Iron Deficiency Anemia in Children with Helicobacter pylori Infection. J. Pediatr. Gastroenterol. Nutr. 2004;38(2):146–51.
  15. Zhang Z.F., Yang N., Zhao G., Zhu L., Zhu Y., Wang L.X. Metaanalysis Effect of Helicobacter pylori eradication on iron deficiency. Chin. Med. J. 2010;123(14):1924–21.
  16. Gisbert J.P., Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol. Ther. 2011;34 (11):1255–68.
  17. Gatta L., Vakil N., Vaira D., Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.
  18. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов. Лечащий врач. 2014; 2:34–40.
  19. Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Айвазова Р.А. Резистентность Helicobacter pylori к компонентам эра-дикационной терапии и пути ее преодо-ления. Фарматека. 2015;2:26–30.


About the Autors


D.N. Andreev – Teaching Assistant of the Department of Propedeutics of Internal Diseases and Gastroenterology MSMSU n.a. A.I. Evdokimov of RMPH, Moscow; e-mail: dna-mit8@mail.ru


Similar Articles


Бионика Медиа